Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Real-world data shows strong adherence to vorasidenib in IDH-mutant glioma. The GLIO-ADHERE study found that most patients who started the oral brain cancer drug after surgery continued taking it as directed for at least a year. The findings suggest vorasidenib's clinical trial success is translating well into everyday practice.
Real-world data shows strong adherence to vorasidenib in IDH-mutant glioma
A new real-world study called GLIO-ADHERE is offering encouraging news about how patients with IDH-mutant glioma are actually taking vorasidenib (Voranigo) outside of clinical trials. Presented at the 2026 SNO Annual Meeting, the retrospective analysis drew on a large U.S. claims database to assess treatment adherence and persistence among 327 eligible patients.
The results show that the vast majority of patients stuck with the therapy. Among those with at least 12 months of follow-up, the median medication possession ratio was 0.99 — nearly perfect — and nearly three-quarters of patients remained on treatment at the one-year mark. Patients who received vorasidenib as their first treatment after surgery showed similarly strong numbers.
By the Numbers
Why it matters: Vorasidenib earned FDA approval in 2024 based on strong clinical trial data, but real-world performance can differ significantly. These findings suggest patients are tolerating and adhering to the drug well in routine practice — a critical signal for clinicians managing this rare brain tumor.